Press release
Europe Viral Vector Manufacturing Market to Hit USD 15.75B by 2034
The Europe Viral Vector Manufacturing Market is experiencing rapid growth due to advancements in gene therapy, increasing demand for cell and gene-based therapies, and the rising adoption of viral vectors in vaccine development. Valued at USD 2.60 Billion in 2024, Europe holds a significant share of the global market. The market is projected to reach USD 15.75 Billion by 2034, growing at a CAGR of 19.74% during the forecast period 2025-2034.
Viral vectors are critical tools for delivering genetic material into target cells for therapeutic purposes, enabling treatments for oncological, neurological, metabolic, and immunological disorders. The expansion of biotechnology and pharmaceutical companies in Europe, along with increased research funding, is driving the adoption of viral vector manufacturing solutions.
Europe Viral Vector Manufacturing Market Overview
The market encompasses the production of various viral vectors, including adenoviral, adeno-associated viral (AAV), lentiviral, and retroviral vectors, for gene therapy, cell therapy, and vaccine applications. Europe is particularly strong in viral vector research and manufacturing due to its robust pharmaceutical industry, advanced bioprocessing capabilities, and regulatory support.
Key Market Highlights
Market Size (2024): USD 2.60 Billion
Projected Market Value (2034): USD 15.75 Billion
CAGR (2025-2034): 19.74%
Major Growth Drivers: Gene therapy adoption, vaccine development, biopharmaceutical expansion, R&D investments
Leading Companies: Lonza Group AG, Merck KGaA, Oxford Biomedica, Novartis AG, Sartorius AG
Get a Free Sample Report with Table of Contents - https://www.expertmarketresearch.com/reports/europe-viral-vector-manufacturing-market/requestsample.
Key Growth Drivers
Advancements in Gene Therapy
Viral vectors are primary delivery vehicles for gene therapies targeting genetic disorders.
Increased clinical trials in Europe boost demand for high-quality viral vectors.
Vectors like AAV and lentiviral vectors are widely used in ex vivo and in vivo therapies.
Rising Cell Therapy Applications
Viral vectors enable genetic modification of cells in CAR-T and other cell-based therapies.
Growing interest in personalized medicine drives production and demand.
Vaccine Development
Viral vectors are key components in modern vaccine platforms, including COVID-19 vaccines.
Adenoviral vectors are extensively used in vaccine research and clinical applications.
Biopharmaceutical Expansion
Europe hosts several leading biotech and pharmaceutical companies investing in viral vector production.
Contract manufacturing organizations (CMOs) are expanding capacity to meet increasing demand.
Technological Advancements
Innovations in vector design, bioreactor scalability, and purification processes.
Adoption of automation, single-use technologies, and quality control solutions improves manufacturing efficiency.
Regulatory and Government Support
EU frameworks support clinical trials and manufacturing of gene therapies.
Funding programs encourage research in rare diseases and regenerative medicine.
Europe Viral Vector Manufacturing Market Segmentation by Type
Adenoviral Vectors
Commonly used in vaccines and gene therapy.
Advantages include high transduction efficiency and large gene-carrying capacity.
Adeno-Associated Viral (AAV) Vectors
Widely used in gene therapy for rare genetic disorders.
Non-pathogenic with long-term gene expression.
Lentiviral Vectors
Used in cell therapy and ex vivo gene modification.
Stable integration into host genome for long-lasting effects.
Retroviral Vectors
Essential for integrating genetic material into dividing cells.
Frequently used in CAR-T therapy and other cell-based treatments.
Others
Includes baculoviral vectors, herpes simplex virus vectors, and hybrid vectors.
Europe Viral Vector Manufacturing Market Segmentation by Application
Gene Therapy
Delivery of therapeutic genes to target cells.
Treats oncological, neurological, and metabolic disorders.
Growth driven by increasing clinical trials and therapy approvals.
Cell Therapy
Modification of patient or donor cells for therapeutic purposes.
Viral vectors are essential in CAR-T and stem cell-based therapies.
Vaccines
Vector-based vaccines are increasingly used for infectious disease prevention.
Accelerated adoption following COVID-19 vaccine success.
Europe Viral Vector Manufacturing Market Segmentation by Therapeutic Area
Oncological Disorders
Vectors used in CAR-T therapy, gene-editing, and targeted cancer therapies.
Growing prevalence of cancer drives research and clinical adoption.
Neurological Disorders
Viral vectors enable gene therapy for diseases like Parkinson's, Alzheimer's, and spinal muscular atrophy.
Increasing R&D investments support market growth.
Metabolic Disorders
Gene therapies for conditions such as hemophilia and lysosomal storage disorders.
Vectors provide stable and targeted delivery.
Immunological Disorders
Autoimmune disease management through genetic modification of immune cells.
Vectors play a key role in ex vivo cell therapy.
Others
Rare disease therapies, ophthalmological disorders, and cardiovascular applications.
Read the Full Report with the Table of Contents - https://www.expertmarketresearch.com/reports/europe-viral-vector-manufacturing-market.
Europe Viral Vector Manufacturing Market Segmentation by End User
Research Organizations
Universities and government research institutes using viral vectors for experimental studies.
High demand for specialized vectors and assay tools.
Biotech and Pharmaceutical Companies
Key segment driving manufacturing and CMO collaborations.
Invest in vector production for therapies and vaccine development.
Others
Hospitals and clinical trial centers.
Contract research organizations (CROs) supporting preclinical and clinical development.
Europe Viral Vector Manufacturing Market Segmentation by Region
United Kingdom
Strong biotech presence and supportive government policies.
Leading research centers driving clinical trial activity.
Germany
Hub for pharmaceutical manufacturing and viral vector production.
Significant investments in gene therapy R&D.
France
Growing adoption of vector-based therapies and clinical trials.
Support from national research funding programs.
Italy
Expansion of contract manufacturing capacity and clinical research infrastructure.
Other European Countries
Spain, Switzerland, and the Netherlands showing moderate growth.
Increasing partnerships between research institutes and biopharma companies.
Competitive Landscape
Key Companies
Lonza Group AG
Merck KGaA
Oxford Biomedica
Novartis AG
Sartorius AG
SIRON Biotech
PlasmidFactory GmbH
Kaneka Eurogentec S.A.
Advanced BioScience Laboratories, Inc.
F. Hoffmann-La Roche AG
Strategic Initiatives
Capacity expansion and investments in GMP-compliant manufacturing.
Mergers and acquisitions to diversify product portfolios.
Development of advanced viral vectors for gene and cell therapy.
Collaborations with clinical research centers and universities.
Adoption of automation, single-use systems, and process optimization technologies.
Market Trends
Rising adoption of AAV and lentiviral vectors for gene therapy.
Expansion of CMO capacity in Europe to meet clinical and commercial demand.
Integration of automation and single-use bioreactors for efficient vector production.
Increasing clinical trials for rare diseases and oncology.
Government funding and regulatory support accelerating therapy approvals.
Europe Viral Vector Manufacturing Market Outlook
The Europe Viral Vector Manufacturing Market is expected to maintain strong growth due to:
Increasing adoption of gene and cell therapies
Growing demand for viral vector-based vaccines
Expansion of biopharmaceutical manufacturing and CMO services
Technological advancements in vector production, purification, and analytics
Strong regulatory and government support in the EU
Forecast for 2034: Market projected to reach USD 15.75 Billion, driven by innovation in viral vector technology and expansion of therapeutic applications.
Explore More Reports
Healthcare Consulting Market - https://bit.ly/43XOegm.
Radiopharmaceuticals Market - https://bit.ly/47DIVVK.
Neurotechnology Market - https://bit.ly/4r7bGBE.
Active Pharmaceutical Ingredients (API) Market - https://bit.ly/4i5ab2V.
Media Contact
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Business Consultant
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
About Us
Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.
Our high-quality, data-driven analysis provides the essential framework for organizations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organization remains agile, proactive, and poised for success in today's competitive market.
Don't miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organization's future success by acquiring one of our Expert Market Research reports today.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Europe Viral Vector Manufacturing Market to Hit USD 15.75B by 2034 here
News-ID: 4292819 • Views: …
More Releases from Expert Market Research
Fertility Supplements Market to Reach USD 5.02B by 2034
What Is Driving the Growth of the Fertility Supplements Market?
The Fertility Supplements Market is experiencing significant growth due to increasing awareness about fertility issues, rising infertility rates, and the growing demand for natural and effective nutritional support to improve reproductive health. Valued at USD 2.26 Billion in 2024, the market is projected to reach USD 5.02 Billion by 2034, growing at a CAGR of 8.30% during the forecast period 2025-2034.
Fertility…
Europe Stem Cell Assay Market to Hit USD 22.07B by 2034
What Is Driving the Growth of the Europe Stem Cell Assay Market?
The Europe Stem Cell Assay Market is witnessing robust growth due to advancements in stem cell research, technological innovations in assays, and rising applications in regenerative medicine and drug development. Valued at USD 6.40 Billion in 2024, Europe holds a significant share of the global market. The market is projected to reach USD 22.07 Billion by 2034, growing at…
Plant Protein Market Size, Share and Forecast for 2025-2034
The plant protein market, valued at around USD 12.05 billion in 2024, is experiencing significant growth as consumer preferences shift toward plant-based diets and alternative protein sources. The market is projected to grow at a compound annual growth rate (CAGR) of 7.50% from 2025 to 2034, reaching an estimated value of USD 24.84 billion by 2034. This growth is driven by the increasing demand for plant-based proteins in food, beverages,…
Latin America Pet Food Market: Evolving Consumer Preferences (2025-2034)
The Latin America pet food market, valued at USD 12.38 billion in 2024, is on a steady upward path as pet ownership rises and consumers shift toward more nutritious, specialized products. With a projected CAGR of 3.70% between 2025 and 2034, the market is on track to reach USD 17.80 billion by 2034. As lifestyles change and pets become integral members of households across the region, demand for high-quality food,…
More Releases for Vector
Growing Prevalence Of Vector-Borne Diseases Fuels Vector Control Market: Pivotal …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Vector Control Market Size Growth Forecast: What to Expect by 2025?
The market size of vector control has been experiencing robust growth in the past years, and it's predicted to increase from $20.53 billion in 2024 to $22.01 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%. Factors such as urbanization…
Global Viral Vector Manufacturing Market Size by Application, Type, and Geograph …
USA, New Jersey- According to Market Research Intellect, the global Viral Vector Manufacturing market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The viral vector manufacturing market is witnessing accelerated growth due to the rising demand for gene therapies and vaccines. These vectors are essential tools…
Prominent Viral Vector Manufacturing Market Trend for 2025: Product Innovation I …
How Are the key drivers contributing to the expansion of the viral vector manufacturing market?
The escalation in the occurrence of both cancer and contagious diseases is anticipated to spur the expansion of the viral vector manufacturing market in the future. An infectious disease is a condition caused by a virus or its harmful byproduct which spreads to a susceptible organism through contact with an infected individual, creature, or object. Cancer…
Emerging Lentiviral Vector Market Trend 2025-2034: Technological Advancements In …
How Is the Lentiviral Vector Market Projected to Grow, and What Is Its Market Size?
The lentiviral vector market will grow from $14.37 billion in 2024 to $16.62 billion in 2025, at a CAGR of 15.7%. This market is expanding due to the growing prevalence of genetic disorders, increasing demand for gene delivery systems, biotech and pharmaceutical investments, and regulatory approvals for related therapies.
The lentiviral vector market is expected to grow…
Viral Vector Manufacturing Market Report 2024 - Viral Vector Manufacturing Marke …
"The Business Research Company recently released a comprehensive report on the Global Viral Vector Manufacturing Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
Adeno-Associated Virus Vector Manufacturing Market - Building Better Therapies: …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Adeno-Associated Virus Vector Manufacturing Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Adeno-Associated Virus Vector Manufacturing provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and…
